- StageZero Life Sciences (SZLS) has launched its COC Plus Program for patients currently in the COC Protocol/TREAT Program
- The programs use diagnostics and telehealth solutions for patients who have cancer
- COC Plus program is centred on nutrition to help address a patient’s specific cancer
- All of the programs are made to be used in conjunction with standard treatments
- StageZero is a healthcare company working to improve the early detection and management of cancer and other chronic diseases
- StageZero Life Sciences, Ltd. (SZLS) is up 23.53 per cent and is trading at $0.10 per share as of 12:53 p.m. ET.
StageZero Life Sciences, Ltd. (SZLS) has launched its COC Plus Program for patients currently in the COC Protocol/TREAT Program.
The programs use “next-generation” diagnostics and telehealth programs to provide clinical mediations for patients who have cancer.
COC Plus program is centred on nutrition and other health interventions to help address a patient’s specific cancer and meant to use with standard care. Although, the company has disclaimed its specialty lab panel and subsequent interventions are not requests made by oncologists or family physicians.
Stage Zero stated its COC Plus Program references lab ordered blood tests to assess a patient’s metabolic and inflammatory status to help decide which interventions to use. It also includes a consultation with an experienced metabolic oncologist to create a strategy.
It is similar in nature to the COC protocol by being made to be used in conjunction with standard-of-care treatments and not as a replacement.
“Many of our patients using the COC Protocol have been asking for expert guidance around nutrition, supplements, and other strategies that is currently not generally available to them,” said James Howard-Tripp, Chairman and CEO of StageZero.
StageZero is a vertically integrated healthcare company working towards improving early detection and management of cancer and other chronic diseases and reduce the risk of developing late-stage illnesses.
StageZero Life Sciences Ltd. (SZLS) is up 23.53 per cent and is trading at $0.10 per share as of 12:53 p.m. ET.
